CN102258531B - Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof - Google Patents
Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof Download PDFInfo
- Publication number
- CN102258531B CN102258531B CN201110102704A CN201110102704A CN102258531B CN 102258531 B CN102258531 B CN 102258531B CN 201110102704 A CN201110102704 A CN 201110102704A CN 201110102704 A CN201110102704 A CN 201110102704A CN 102258531 B CN102258531 B CN 102258531B
- Authority
- CN
- China
- Prior art keywords
- peg400
- pharmaceutical composition
- meglumine
- gram
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims abstract description 18
- 229960003194 meglumine Drugs 0.000 title claims abstract description 18
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 4
- 229930195725 Mannitol Natural products 0.000 claims abstract description 4
- 239000000594 mannitol Substances 0.000 claims abstract description 4
- 235000010355 mannitol Nutrition 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 14
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 12
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- HYMXALLEHXXORK-HTDNVCFESA-N (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 HYMXALLEHXXORK-HTDNVCFESA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicinal composition containing adenosine cyclophosphate and meglumine and a preparation method thereof. The medicinal composition comprises adenosine cyclophosphate serving as an active ingredient, meglumine serving as a stabilizer and mannitol serving as a skeleton in a certain mixing ratio. The composition minimizes the degradation of adenosine cyclophosphate and therefore protects the stability, effectiveness and safety of the medicines.
Description
Background technology
Adenosine cyclophosphate (cAMP) is the important substance of participating in substance metabolism in the body, regulating cell physics and chemistry and biological function, is life-information transmission and the second message,second messenger with hormonal action.Its most important receptor protein is a protein kinase, can make multiple different substrate protein white matter phosphorylation, and show function very widely.But adenosine cyclophosphate is slightly soluble in water, and is almost insoluble in ethanol or ether.The adding of stabilizing agent meglumine makes adenosine cyclophosphate be combined into meglumine adenosine cycle phosphate with it, and the water solublity of synthetic meglumine cyclic adenylate molecule strengthens than cAMP, and the cAMP stability in the molecule also increases, and is novel cAMP class positive inotropic medicament.
Meglumine can increase the fat-soluble of cAMP, makes the latter be prone to infiltrate through in the cell, and meglumine also has certain inhibitory action to phosphodiesterase simultaneously, makes it the decomposition of cAMP is reduced, so the positive inotropic action of meglumine adenosine cycle phosphate is stronger than the cAMP of a great deal of.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that contains adenosine cyclophosphate and meglumine, can significantly improve medicine stability, it contains following component:
Above-mentioned compositions, the preferred 0.1-0.8 gram of said PEG400.
Above-mentioned compositions, the preferred 0.4-0.8 gram of said PEG400.
Above-mentioned compositions, preferred 0.4 gram of said PEG400.
Above-mentioned compositions, preferred 0.6 gram of said PEG400.
Above-mentioned compositions, preferred 0.8 gram of said PEG400.
Above-mentioned preparation of drug combination method is characterized in that: the meglumine, mannitol and the PEG400 that take by weighing recipe quantity add the room temperature water for injection of recipe quantity 80% to sterile chamber, stir to make dissolving; Add adenosine cyclophosphate again, stir and to make dissolving, take by weighing about 20 minutes of the equidirectional continuous stirring of active carbon of amount of preparation 0.05%, filter carbon removal (the solution pH value is in the 5.5-7.0 scope) back and cross 0.22 micron microporous filter membrane fine straining; Supply the water for injection standardize solution then; After measuring intermediate qualified by standard in accordance with the law; Subsequent filtrate is filled in the cillin bottle; After being provided with the related parameter index according to the freeze-drying curve of product, product is put pre-freeze in the freezer dryer, after-45 ℃ of pre-freeze 2-3 hours, evacuation; Guarantee that vacuum is about 10 Pascals, slowly be warming up to-25 ℃ approximately, kept about 8 hours, slowly heat up again; Carry out drying again, temperature rises to 30 ℃, and lyophilization is jumped a queue after finishing; Roll lid, lyophilizing 30-40 hour, both.Pharmaceutical composition of the present invention can exist with the freeze-dried powder form.
The present invention has improved the proportioning of meglumine in the meglumine adenosine cycle phosphate; The adding of high dose meglumine has effectively improved the stability (referring to data in the table 3) of CCP; Thereby guaranteed the effectiveness and the safety of CCP, the meglumine that increases simultaneously can make the decomposition of adenosine cyclophosphate reduce again to the inhibitory action of phosphodiesterase.
The specific embodiment
Method is for a better understanding of the present invention further set forth the present invention and advantage thereof through embodiment and experimental evidence below.
The embodiment proportioning
The preparation of reference examples 1-2 and embodiment 1-7: the meglumine, mannitol and the Polyethylene Glycol that take by weighing recipe quantity add the room temperature water for injection of recipe quantity 80% to sterile chamber, stir to make dissolving; Add adenosine cyclophosphate again, stir and to make dissolving, take by weighing about 20 minutes of the equidirectional continuous stirring of active carbon of amount of preparation 0.05%, filter carbon removal (the solution pH value is in the 5.5-7.0 scope) back and cross 0.22 micron microporous filter membrane fine straining; Supply water for injection then and be settled to 2000ml; After measuring intermediate qualified by standard in accordance with the law.Subsequent filtrate is filled in the cillin bottle; After being provided with the related parameter index according to the freeze-drying curve of product, product is put pre-freeze in the freezer dryer, after-45 ℃ of pre-freeze 2-3 hours, evacuation; Guarantee that vacuum is about 10 Pascals, slowly be warming up to-25 ℃ approximately, kept about 8 hours, slowly heat up again; Carry out drying again, temperature rises to 30 ℃, and lyophilization is jumped a queue after finishing; Roll lid (about 35 hours of freeze-drying time), examine entirely by preparation quality standard, and pack finished product.
Experimental example 1: related experiment of the present invention
To carry out undue toxicity's inspection by two appendix XIC of Chinese Pharmacopoeia version in 2005 according to the freeze-dried powder (embodiment 1) that the present invention processes, the product experimental result of going on the market at present is as shown in table 1 below:
Undue toxicity's experiment of table 1 lyophilized injectable powder
To add the chlorination sodium injection according to the freeze-dried powder (embodiment 1-7) that the present invention processes and process the solution that contains 18.8mg among every 1m1; Carry out pyrogen test by two appendix XI of Chinese Pharmacopoeia version in 2005 D; Dosage is slowly injected 1ml by the every 1kg of rabbit body weight; Intensification can find out from above data less than 0.2 ℃, and the undue toxicity and the pyrogen of the freeze-dried powder of processing according to the present invention are all up to specification.
The 30-35 ℃ of storage of dried frozen aquatic products simulate poor condition that will make according to the present invention, and with embodiment its stability relatively, experimental result is as shown in table 2:
The stability data of table 2 freeze-dried products of the present invention
Through the description of test embodiment of the invention after 90 days content be significantly higher than reference examples, and in process, content is more stable, the prompting present composition has remarkable effect to improving medicine stability.
The dried frozen aquatic products that will make according to the present invention is by 15-20 ℃ of storage of the regulation storage requirement upper limit, and with control Example its stability relatively, experimental result is as shown in table 3:
The stability data of table 3 freeze-dried products of the present invention (continuing)
Through the description of test embodiment of the invention after 90 days content be significantly higher than reference examples, and in process, content is more stable, the prompting present composition has remarkable effect to improving medicine stability.Can find out that from table 2 and 3 freeze-dried products of the present invention all can keep content and related substance up to specification under the storage requirement of regulation, also can guarantee that product under the of short duration hot weather influence of transportation, plays the effect that delays to degrade simultaneously.With reference examples relatively, effect duration of the present invention intensive amount and the stability of related substance suitable remarkable advantages is all arranged.
Claims (7)
1. pharmaceutical composition that contains adenosine cyclophosphate and meglumine is characterized in that containing following component:
2. pharmaceutical composition according to claim 1 is characterized in that said PEG400 is the 0.1-0.8 gram.
3. pharmaceutical composition according to claim 2 is characterized in that said PEG400 is the 0.4-0.8 gram.
4. pharmaceutical composition according to claim 3 is characterized in that said PEG400 is 0.4 gram.
5. pharmaceutical composition according to claim 3 is characterized in that said PEG400 is 0.6 gram.
6. pharmaceutical composition according to claim 3 is characterized in that said PEG400 is 0.8 gram.
7. the arbitrary described preparation of drug combination method of claim 1-6, it is characterized in that: the meglumine, mannitol and the PEG400 that take by weighing recipe quantity add the room temperature water for injection of recipe quantity 80% to sterile chamber, stir to make dissolving; Add adenosine cyclophosphate again, stir and to make dissolving, take by weighing about 20 minutes of the equidirectional continuous stirring of active carbon of amount of preparation 0.05%, after the solution pH value is the carbon removal of 5.5-7.0 scope inner filtration, cross 0.22 micron microporous filter membrane fine straining; Supply the water for injection standardize solution then; After measuring intermediate qualified by standard, subsequent filtrate is filled in the cillin bottle in accordance with the law; After being provided with the related parameter index according to the freeze-drying curve of product, product is put pre-freeze in the freezer dryer, after-45 ℃ of pre-freeze 2-3 hours, evacuation; Guarantee that vacuum is about 10 Pascals, slowly be warming up to-25 ℃ approximately, kept about 8 hours, slowly heat up again; Carry out drying again, temperature rises to 30 ℃, and lyophilization is jumped a queue after finishing; Roll lid, lyophilizing 30-40 hour, both.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110102704A CN102258531B (en) | 2011-04-12 | 2011-04-12 | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110102704A CN102258531B (en) | 2011-04-12 | 2011-04-12 | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102258531A CN102258531A (en) | 2011-11-30 |
| CN102258531B true CN102258531B (en) | 2012-09-19 |
Family
ID=45005497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110102704A Expired - Fee Related CN102258531B (en) | 2011-04-12 | 2011-04-12 | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102258531B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488650B (en) * | 2011-12-19 | 2013-07-17 | 王保明 | Adenosine cyclophosphate pharmaceutical composition and preparation method thereof |
| CN102796156B (en) * | 2012-08-24 | 2014-07-30 | 宁辉 | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof |
| CN103142476B (en) * | 2013-03-21 | 2014-11-12 | 青岛正大海尔制药有限公司 | Calcitriol suspension and preparation method thereof |
| CN104546851B (en) * | 2013-10-29 | 2018-01-02 | 北京韩美药品有限公司 | A kind of particulate composition and preparation method thereof, preparation |
| CN104706655B (en) * | 2015-03-31 | 2018-08-14 | 山东北大高科华泰制药有限公司 | Meglumine cyclic adenosine for injecta powder-injection pharmaceutical composition and preparation method |
| CN105213329B (en) * | 2015-11-10 | 2018-03-27 | 瑞阳制药有限公司 | Meglumine cyclic adenosine for injecta freeze-dried powder and preparation method thereof |
| CN105748414A (en) * | 2016-03-02 | 2016-07-13 | 张光泉 | Anti-infection micafungin freeze-drying composition and preparation method thereof |
| EP4058026A4 (en) * | 2019-11-12 | 2023-12-06 | American Regent, Inc. | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1579413A (en) * | 2004-02-11 | 2005-02-16 | 江卫世 | Meglumine adenosine cyclophosphate for injection and its preparing method |
| CN1923180A (en) * | 2006-09-22 | 2007-03-07 | 江苏万邦生化医药股份有限公司 | Meglumine cyclic adenosine for injecta and its preparing process |
-
2011
- 2011-04-12 CN CN201110102704A patent/CN102258531B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1579413A (en) * | 2004-02-11 | 2005-02-16 | 江卫世 | Meglumine adenosine cyclophosphate for injection and its preparing method |
| CN1923180A (en) * | 2006-09-22 | 2007-03-07 | 江苏万邦生化医药股份有限公司 | Meglumine cyclic adenosine for injecta and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102258531A (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258531B (en) | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof | |
| CN101606934B (en) | Bendamustine hydrochloride compound | |
| CN101411710A (en) | Pemetrexed disodium freeze-dried injection and preparation method thereof | |
| CN101791310B (en) | Vinpocetine medicine composition and preparation method thereof | |
| CN102525963A (en) | Netilmicin sulfate lyophiled powder injection and preparation method thereof | |
| CN101756897B (en) | Clindamycin hydrochloride injection and preparation method thereof | |
| CN104257615A (en) | Dezocine freeze-dried pharmaceutical composition and preparation method thereof | |
| CN102178681A (en) | Injection calcium folinate composite and preparation method thereof | |
| CN106389353A (en) | Compound ammonium glycyrrhetate S for injection, and preparation method therefor | |
| CN102488650B (en) | Adenosine cyclophosphate pharmaceutical composition and preparation method thereof | |
| CN103040855B (en) | Pharmaceutical composition of fludarabine phosphate and preparation method thereof | |
| CN103006586A (en) | Epirubicin hydrochloride lyophilized injectable powder and preparation method thereof | |
| CN103055305B (en) | A lyophilized preparation of a cytochrome C-containing pharmaceutical composition for injection and a preparation method thereof | |
| CN105434369A (en) | High-solubility and high-stability chlorogenic acid freeze-dried powder injection | |
| CN102367229B (en) | Ethylenediamine diaceturate compound and pharmaceutical composition thereof | |
| CN101862319B (en) | Docetaxel combination for injection and preparation method thereof | |
| CN103494779B (en) | Andrographolide powder preparation for injection and preparation method thereof | |
| CN102697740B (en) | Gemcitabine hydrochloride lyophilized powder for injection and preparation method thereof | |
| CN101152174B (en) | Stable rifamycin sodium injection prescription and preparing method of the same | |
| CN102988305B (en) | Medicinal composition containing meglumine cyclic adenosine monophosphate compound | |
| CN102988954B (en) | Medicinal composition containing thymopentin compound | |
| CN103040765A (en) | Pharmaceutical composition containing adenosine disodium triphosphate and preparation method of pharmaceutical composition | |
| RU2711337C1 (en) | Solid pharmaceutical composition and a method for production thereof | |
| CN100450476C (en) | Electrolyte complementary medical combination for injection | |
| CN101804034A (en) | Rabeprazole sodium powder injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO ZHONGZHI PHARMACEUTICAL MARKETING SCHEMING Free format text: FORMER OWNER: NING HUI Effective date: 20130627 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266034 QINGDAO, SHANDONG PROVINCE TO: 264000 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130627 Address after: 264000 Shandong province Qingdao City, No. 129 Fuzhou Road, two floor Patentee after: Qingdao Zhongzhi pharmaceutical marketing planning Co. Ltd. Address before: 266034 Shandong province Qingdao City, No. 129 Fuzhou Road, International Building Room 202 Patentee before: Ning Hui |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111130 Assignee: Shandong Luye Pharma Co., Ltd. Assignor: Qingdao Zhongzhi pharmaceutical marketing planning Co. Ltd. Contract record no.: 2014990000098 Denomination of invention: Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof Granted publication date: 20120919 License type: Common License Record date: 20140303 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 Termination date: 20190412 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |